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Abstract 
Myelodysplastic syndromes (MDS) are heterogeneous hematopoietic disorders 
characterized by bone marrow failure, cytopenias and a tendency to transform into acute 
myeloid leukemia. Anemia and transfusional need can be major problems for patients with 
MDS. Erythropoiesis stimulating agents (ESAs) therapy is a standard treatment for the 
anemia of most patients with MDS; however not all MDS patients respond to ESAs and a 
majority of patients eventually relapse after an initial response. This study aimed to identify 
the clinical impact of TFR2 and EPOR expression in bone marrow cells at diagnosis in 
MDS patients. We report the expression pattern of TFR2α and TFR2β in various subtype 
of MDS in comparison to that of EPOR. We provide evidence that TFR2 expression could 
be a potential molecular marker associated with response to erythropoietin (Epo) 
treatments in MDS patients and that lower TRF2 expression is associated with the poorest 
survival in MDS. 
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Myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by 
ineffective bone marrow hematopoiesis, peripheral blood cytopenias and substantial risk 
for transformation into acute myeloid leukemia (Tefferi et al, 2009). 
Although scoring systems are used to predict the prognosis of MDS (Greenberg et al, 
1997; Greenberg et al, 2012), they provides information that unfortunately do not always 
coincide with clinical outcome. Percentage of blasts (>10%) and unfavorable cytogenetic 
abnormalities are the strongest predictors for poor outcome and are associated with high 
risk or disease progression to acute leukemia. Those patients, if possible, should undergo 
to allogenic stem cell transplantation or, if not eligible, to hypomethylating agents 
treatment.  
In lower-risk MDS patients, the main clinical problem is chronic anemia. Anemia responds 
in 30–50% of the cases to erythropoiesis-stimulating agents (ESAs). Some prognostic 
factors of erythroid response to ESAs have been well identified, with better response rates 
in patients with no or limited red blood cell (RBC) transfusion requirement, low baseline 
serum EPO level and no-aberrant myeloid blast at flow cytometry (Park et al, 2008). For all 
these reason, the clinical care of MDS patients is still challenging, mainly due to MDS 
phenotypic heterogeneity and lack of well-established markers that effectively monitor 
MDS natural history. Therefore, in the lower-risk MDS subset, predicting at diagnosis 
patients with risk of treatment failure are pivotal to personalizing treatments in order to 
improve the quality of life and to prolong survival. 
Transferrin receptor 2 (TFR2), homologous to TFR1, is a protein mutated in 
hemocromatosis type 3 and contributes to regulate hepcidin in the liver (Ramos et al, 
2011). It is also expressed in erythroid cells (declining as the erythroid progenitors mature) 
and in myeloid malignant disorders (Kawabata et al, 2001). TFR2 associates with 
erythropoietin receptor (EPOR) (Forejtnikova et al, 2010) and is required for efficient 
erythropoiesis (Nai et al, 2015; Nai et al, 2014). Unlike TFR1, the TFR2 gene gives rise to 
two isoforms referred to as TFR2α (full-length) and a shorter TFR2β (Kawabata et al, 
1999). 
This retrospective study aimed to investigate whether TFR2 isoforms are differentially 
expressed in patients with MDS, and if so, whether TFR2 is associated with patient’s 
clinical outcomes. Moreover, in the same cohort of patients, we focused on EPOR 
expression level since it was previously reported that TFR2 could act as an escort protein 
for this receptor, being required for EPOR efficient cell surface expression (Forejtnikova et 
al, 2010). Bone marrow (BM) aspirates were obtained from 6 individuals with non-
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malignant hematological disorders (4 males, 2 females, median age of 57 years ranging 
from 45 to 73) and from 42 treatment-naive patients at the diagnosis of MDS. Diagnosis of 
MDS was made according to the World Health Organization (WHO) criteria (Vardiman et 
al, 2009). The patient group consisted in 28 male and 14 female with a median age of 71 
years (range 49-85) and a WHO 2008 distribution as follows: RA n= 19, RARS n=2, 
RCMD n=6, RAEB‐1 n=8, RAEB-2 n=7.  
After informed consent and ethical approval (EMATO/TFR2-RE, code 92/2015) were 
obtained, RNA was extracted from total bone marrow cells collected at diagnosis and 
TFR2α, TFR2β and EPOR expression were quantified by quantitative Real-Time PCR, in 
comparison to that of RNA Universal (Stratagene), normalized for ABL1. Primer 
sequences were: a) 5’TTTCCACCAGGGCAGACTCT3’, b) 5’TCCCGAAGGCTGGTTTG3’ 
for TFR2α; c) 5’AGTCCCCACCTCTCCCCGCT3’, d) 5’GTGTTGGGGTGAGCCGGATC3’ 
for TFR2β; e) 5’GAGCGTACAGAGGGTGGAGA3’, f) 5’AGGATGACCACGAGGATGAG3’ 
for EPOR.  The relative gene expression was calculated using the equation, 2-∆∆Ct. 
Statistical analyses were performed using GraphPad Prism software. Comparisons 
between groups were performed by means of Mann–Whitney U-test (nonparametric 
analysis), and P values <0.05 indicated a significant difference. 
In MDS patients TFR2α  and TFR2β showed higher variability in expression (TFR2α 
6.08±5.58; TFR2β 3.15±1.16) than in non-malignant BM cells (TFR2α 8.23±2.97; TFR2β 
3.51±0.47). Due to MDS morphological and clinical heterogeneity, we evaluated TFR2α 
and TFR2β expression in the different WHO subgroups (Figure 1A-B). Among the different 
MDS subtypes, the expression of TFR2α and TFR2β was significantly lower in RAEB2 
(TFR2α 4.44±2.11; TFR2β 2.15±0.59) when compared with controls (p<0.05 and p<0.005, 
respectively). A similar expression level was also seen in RARS but the limited number of 
patients with this condition precludes any statistical analysis. TFR2α and TFR2β 
expression was not correlated with total white blood cells, neutrophils and platelets counts, 
age at diagnosis and no significant differences were observed between sex (not shown). 
We next compared TFR2 expression with that of EPOR. Similarly to TFR2, EPOR 
expression in bone marrow cells varied more widely in MDS patients (18.00±2.90) than in 
non-malignant individuals (17.31±1.62) and was statistically lower in RAEB2 (8.18±0.99, 
p<0.005) (Figure 1C). In addition, conducting a Spearman’s correlation analysis on the 
mRNA expression of both TRF2 isoforms and EPOR, we found that TFR2α and TFR2β 
expression is positively correlated with EPOR expression (Figure 1D-E). 
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To assess the clinical implication of TFR2 and EPOR expression in bone marrow cells, we 
categorized MDS patients into four expression sub-groups according to TFR2 and EPOR 
expression relative to the mean of the non-malignant BM and we analyzed the erythroid 
response in the cohort of patients that underwent to Epo treatment. We noticed that only 
patients with at least one of the TFR2 isoforms and EPOR levels comparable to normal 
controls reached an increase in hemoglobin level of ≥ 1.5 g/dl after 12 weeks of treatment. 
Instead, all non-responders, with the exception of 2 patients high-expressing TFR2/EPOR, 
had low levels of TFR2 or EPOR mRNA (Figure 2A). 
We finally tested the effects of TFR2α, TFR2β and EPOR expression on survival in 
RAEB1-2 and RCMD (Figure 2B-C-D). Comparisons between Kaplan-Meier curves were 
carried out by log-rank test. In the first year of follow-up, patients with very low/low TFR2α 
or TFR2β expression levels had a significantly worse overall survival (OS) than those with 
normal/high TFR2 expression (p<0.05 and p<0.01 respectively). No significant difference 
was noted between patients with low or normal/high EPOR expression, although there was 
a tendency for poorer survival in the very low/low EPOR expression group. 
Ever since it was demonstrated that TFR2 is a component of EPOR complex (Forejtnikova 
et al, 2010), there has been interest on understanding its extra-hepatic function. The TFR2 
erythroid function has been recently described in normal erythropoiesis in mouse models 
lacking systemic or hematopoietic TFR2 (Nai et al, 2015; Nai et al, 2014). Considering the 
natural history of the disease, MDS are suitable models for studying how TFR2 expression 
change in clonal hematologic disorders and how it is related to EPOR. Moreover, as iron 
overload can have an adverse effect on hematopoietic precursors, knowing how the 
expression of an iron-related gene is modulated is important to understand how iron 
metabolism and hematopoiesis interact. We showed that TFR2α, TFR2β and EPOR have 
a much more variable pattern of expression in MDS compared to normal and that, 
differently compared to what previously reported (Kawabata et al, 2001), their expression 
are significantly lower in high risk MDS like RAEB2. Therefore, the lack of TFR2 could 
impair the entire myeloid lineage differentiation, as it does in human erythroid progenitors 
delaying erythroid terminal differentiation (Forejtnikova et al, 2010). 
The data presented here demonstrate that the reduction of TFR2 isoforms mRNA is 
associated with poorer survival in patients with high grade MDS. This is in agreement with 
the work of Nakamaki et al. (Nakamaki et al, 2004) that found that de-novo acute myeloid 
leukemia patients with high levels of both TFR2 isoforms survived significantly longer. 
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Furthermore, we established a positive correlation between TFR2 and EPOR mRNA 
expression implying a possible co-regulation or interplay at transcriptional level of these 
two interacting proteins. Finally, we reported that TFR2 and EPOR expression could 
provide information on Epo treatment response since this was achieved only in individuals 
with both TFR2 and EPOR mRNA levels similar to normal. High level of expression seems 
to be also deleterious, probably due to an altered receptor signalling. 
Limitations of our study include the relatively small number of patients and hence limited 
amount of cases used for the treatment-response analysis. Nevertheless, the level of bone 
marrow TFR2 mRNA seems to offer additional information on predicting Epo treatment 
response. However, before considering TFR2 and EPOR expression levels in clinical 
decision making, additional validation studies, are needed, also to define optimal cut-off 
levels. 
In conclusion, our data provide evidence suggesting that TFR2 and EPOR expression 
could be used as potential molecular markers for a better management of MDS patients 
clinical course. To our knowledge, this is the first study to analyze TFR2 clinical value in 
MDS patients. 
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FIGURES LEGENDS. 
 
Figure 1. TFR2 and EPOR gene expression in newly diagnosed MDS BM samples. 
(A-C) Real time analysis of TFR2α, TFR2β and EPOR transcripts in subtypes of MDS 
according to WHO classification, compared to non-malignant BM samples. 
**p-value<0.01. The lines indicate mean value of each group. 
(D-E) Spearman’s correlation analysis on the mRNA expression of TFR2α, TFR2β and 
EPOR in our cohort of MDS patients. R and p values are indicated. Color and shape code 
of each individual point in the graphs are the same reported in figure 1 A-C. 
 
Figure 2. Potential value of TFR2 in the clinical diagnostic application of MDS patients. 
(A) Clinical and laboratory parameters of myelodysplastic patients treated with 
erythropoietin. WHO = World Health Organization classification of myelodysplastic 
syndromes, Dosage = erythropoietin dosage, RA = refractory anemia, RCMD = refractory 
cytopenia with multilineage dysplasia, RAEB-1 = refractory anemia with excess of blasts 
type 1, RAEB-2 = refractory anemia with excess of blasts type 2, RARS = refractory 
anemia with ringed sideroblasts, Hb = hemoglobin, ∆Hb = hemoglobin variation after 12 
weeks of treatment. Patients that responded to Epo treatment are highlighted in red. MDS 
patients were categorized into four expression sub-groups according to TFR2 and EPOR 
expression relative to the mean of the non-malignant BM cells, as follows: “very low” group 
when TFR2 and EPOR levels were less than minus two standard deviations (SD) from the 
mean of non-malignant BM; “low” between minus two and minus one SD; “normal” 
between minus and plus one SD; “high” more than one SD. (B-C-D) Kaplan-Meier survival 
curves for MDS RAEB1-2/RCMD patients based on TFR2α, TFR2β or EPOR expression 
level. *p-value<0.05 analyzed by log-rank test. 
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Figure 2. 
Case	  #	   WHO	   Dosage	   Transfusion	  need	   Hb	  (g/dL)	   ∆Hb	  (g/dL)	   TFR2α	  	   TFR2β	   EPOR	  
1	   RA	   40000	  U/week	   no	   10,5	  -­‐>	  	  12,4	   1,9	   low	   normal	   normal	  
6	   RA	   40000	  U/week	   no	   9,3	  -­‐>	  9,9	   0,6	   high	   high	   high	  
12	   RA	   40000	  U/week	   no	   8,8	  -­‐>	  9,2	   0,4	   	  very	  low	   very	  low	   very	  low	  
13	   RARS	   40000	  U/week	   3RCB	  units/month	   8,2	  -­‐>	  8,8	   0,6	   low	   	  very	  low	   	  very	  low	  
17	   RA	   40000	  U/week	   no	   9,3	  -­‐>	  12,4	   3,1	   normal	   	  very	  low	   normal	  
25	   RCMD	   40000	  U/week	   no	   9,7	  -­‐>	  10	   0,3	   	  very	  low	   	  very	  low	   	  very	  low	  
41	   RA	   40000	  U/week	   no	   9,2	  -­‐>	  10,5	   1,3	   high	   high	   high	  
	  	   	  
2	   RAEB	  1	   80000	  U/week	   no	   9,7	  -­‐>	  10,6	   0,9	   low	   	  very	  low	   low	  
10	   RAEB	  1	   80000	  U/week	   3RCB	  units/month	   6,8-­‐>	  6,7	   -­‐0,1	   	  very	  low	   low	   	  very	  low	  
11	   RA	   80000	  U/week	   3RCB	  units/month	   7,5	  -­‐>	  8,1	   0,6	   low	   normal	   low	  
14	   RAEB	  1	   80000	  U/week	   4RCB	  units/month	   7,3	  -­‐>	  6,8	   -­‐0,5	   	  very	  low	   	  very	  low	   	  very	  low	  
26	   RCMD	   80000	  U/week	   no	   9,1	  -­‐>	  13,3	   4,2	   normal	   high	   normal	  
29	   RAEB	  2	   80000	  U/week	   2RCB	  units/month	   7,9	  -­‐>	  8,3	   0,4	   	  very	  low	   	  very	  low	   	  very	  low	  
34	   RA	   80000	  U/week	   no	   8,3	  -­‐>	  11,2	   2,9	   normal	   high	   normal	  
37	   RCMD	   80000	  U/week	   4	  RCB	  units/month	   7-­‐>	  7,2	   0,2	   	  very	  low	   normal	   	  very	  low	  
39	   RAEB	  1	   80000	  U/week	   no	   10,1	  -­‐>	  12,2	   2,1	   high	   normal	   normal	  
40	   RA	   80000	  U/week	   2	  RCB	  units/month	   	  8,5-­‐>	  7	   -­‐1,5	   normal	   normal	   low	  
A	  
B	   C	   D	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